From Nasdaq: 2025-05-12 17:02:00

Teva Pharmaceutical Industries (NYSE: TEVA) saw a 6% surge in share price after a positive recommendation from JPMorgan Chase analyst Chris Schott, who upgraded the stock to overweight and raised the price target to $23. The company’s cost-cutting measures and potential in branded products are driving optimism for future growth. Analysts forecast a 3% increase in revenue for 2025 and a 9% rise in per-share net income. While Teva remains a key player in generic drugs, its focus on branded products and improved financials are boosting confidence in its future prospects.



Read more at Nasdaq: Why Teva Pharmaceuticals Stock Blasted 6% Higher Today